|1.||Pelletier, Jerry: 8 articles (04/2015 - 10/2009)|
|2.||Bitterman, Peter B: 5 articles (07/2015 - 06/2004)|
|3.||Sonenberg, Nahum: 5 articles (04/2015 - 06/2004)|
|4.||Walsh, Derek: 5 articles (01/2011 - 03/2004)|
|5.||Polunovsky, Vitaly A: 4 articles (07/2015 - 06/2004)|
|6.||Mohr, Ian: 4 articles (01/2011 - 03/2004)|
|7.||Tillu, Dipti V: 3 articles (05/2015 - 11/2010)|
|8.||Price, Theodore J: 3 articles (05/2015 - 11/2010)|
|9.||Kratzke, Robert A: 3 articles (08/2014 - 03/2011)|
|10.||Patel, Manish R: 3 articles (08/2014 - 03/2011)|
02/01/2014 - "In this study, we found that decreasing the abundance or activity of eIF4F from the start of infection inhibits HCMV replication. "
02/01/2014 - "However, during the late stage of infection the translation efficiency of viral mRNAs does not correlate with the abundance or activity of the host eIF4F complex. "
02/01/2014 - "Together, our data show that the translation of host eIF4F-dependent mRNAs remains dependent on eIF4F activity during HCMV infection. "
02/01/2014 - "A global analysis of the translation efficiency of HCMV mRNAs during the late stage of infection found that eIF4F disruption had a minimal impact on the association of HCMV mRNAs with polysomes but significantly diminished the translation efficiency of eIF4F-dependent host transcripts. "
02/01/2014 - "In contrast, eIF4F inhibition decreased the translation of representative host eIF4F-dependent mRNAs during the late stage of infection. "
08/01/2014 - "In this study, disrupting the eIF4F complex by antagonizing the eIF4E-mRNA-cap interaction is assessed as a therapy for mesothelioma. "
01/01/2013 - "In this study, disabling the eIF4F complex by targeting eIF4E with eIF4E-specific antisense oligonucleotide (4EASO) is assessed as a therapy for mesothelioma. "
08/01/2014 - "Mesothelioma cells were treated with 4Ei-1, a membrane permeable prodrug that when converted to the active drug, 7-benzyl guanosine monophosphate (7Bn-GMP) displaces capped mRNAs from the eIF4F complex. "
01/01/2013 - "4EASO is a novel drug that causes apoptosis and selectively reduces eIF4E levels, eIF4F complex formation, and proliferation of mesothelioma cells. "
08/04/2009 - "Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma."
10/01/2014 - "Taken together, SGP-2 exerts anti-tumor effect through intrinsic apoptotic pathway controlled by ERK/eIF4F/Bcl-XL pathway."
09/04/2014 - "Combinations of drugs targeting BRAF (and/or MEK) and eIF4F may overcome most of the resistance mechanisms arising in BRAF(V600)-mutant cancers. "
09/04/2014 - "Strikingly, inhibiting the eIF4F complex, either by blocking the eIF4E-eIF4G interaction or by targeting eIF4A, synergizes with inhibiting BRAF(V600) to kill the cancer cells. "
01/01/2013 - "m7GTP-Sepharose-binding assay revealed that Src activity is required to form eIF4F complex which is necessary for Cap-dependent translation in α6β4 expressing human cancer cells. "
09/01/2012 - "Here, we show that 80% of tumors and cell lines featuring amplified ERBB2 display an aberrantly activated eIF4F. "
04/20/2015 - "These studies demonstrate that the eIF4F complex is deregulated in aggressive lymphoma and that dual mTOR therapy has therapeutic potential in these patients."
04/19/2012 - "We find elevated Myc levels are associated with deregulated eIF4F activity in the prelymphomatous stage of the Eμ-Myc lymphoma model. "
03/01/2011 - "Expression of components of the eIF-4F complex and unphosphorylated and phosphorylated 4E-BP1 was confirmed using Western immunoblotting on lysates of frozen lymphoma samples and reactive tissues. "
06/14/2011 - "Myc-driven lymphomas contain PKCβII and phosphorylated eIF6; eIF6 is phosphorylated by tumor-derived PKCβII, but not by the eIF4F activator mTORC1. "
01/01/2013 - "We report here that hippuristanol (Hipp), a translation initiation inhibitor that selectively inhibits the eIF4F RNA helicase subunit, eIF4A, resensitizes Eμ-Myc lymphomas to DNA damaging agents, including those that overexpress eIF4E-a modifier of rapamycin responsiveness. "
05/08/2012 - "Our results suggested that the use of inhibitors that directly target the translation initiation complex eIF4F could represent a potential novel approach for multiple myeloma therapy."
09/16/2014 - "Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma."
02/28/2015 - "This study is the first to directly assess the relative contribution of eIF4F components to the expressed cellular proteome, transcription factors, microRNAs, and phenotype in a malignancy known for extensive protein synthesis-multiple myeloma (MM). "
|1.||Eukaryotic Initiation Factor-4E
|2.||Peptide Initiation Factors (Initiation Factor)
|3.||Eukaryotic Initiation Factor-4G (Eukaryotic Initiation Factor 4G)
|4.||RNA Cap-Binding Proteins (Cap Binding Protein)
|7.||Protein Isoforms (Isoforms)
|8.||Transcription Factors (Transcription Factor)
|10.||erlotinib (CP 358,774)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)